COMP <GO>
PFE vs UNH // NET PROFIT MARGIN
Pfizer Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: PFE 4
— UNH 10
▲ NET PROFIT MARGIN LEADER: PFE
LAST: $30.52 (+1.90%) • MKT CAP: $170.71B
net-margins
12.40%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
net-margins
3.14%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PFE VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PFE | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 88.57% | -14.27 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.10% | 11.47% | -6.37 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.7x | 16.4x | +3.25 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.32% | 6.48% | -1.16 | UNH | /fcf-yield <GO> |
| Operating Margin | 15.10% | 4.82% | +10.28 | PFE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 12.40% | 3.14% | +9.26 | PFE | /net-margins <GO> |
| Revenue Growth (YoY) | -1.60% | 6.46% | -8.06 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.10 | 3.12 | -1.02 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.74% | +0.36 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.5 | 56.0 | +10.49 | PFE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.33 | +0.72 | PFE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 17.1x | +3.41 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $170.71B | $364.66B | -$193.95B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PFE REV | UNH REV | PFE GROSS % | UNH GROSS % | PFE FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.58B | $447.57B | 74.3% | 88.7% | $9.07B | $16.07B |
| FY 2024 | $63.63B | $400.28B | 71.9% | 88.3% | $9.84B | $20.70B |
| FY 2023 | $50.91B | $371.62B | 44.0% | 89.6% | $6.41B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PFE // BETA 1.05
UNH // BETA 0.33